Physician profile
Na Vang
NPI 1518399344
$2,528.09
in general payments reported to CMS, 2019-2025
25 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $558 · 2023: $70.74 · 2024: $278 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $536.70 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $317.62 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $267.85 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.85 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $143.88 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $140.50 | 2019-2025 | Jardiance, Kisunla, Zepbound |
| Sanofi-Aventis U.S. LLC | $130.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $86.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $84.87 | 2019-2024 | Arexvy |
| Dexcom, INC. | $70.74 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $66.08 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $65.30 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $62.44 | 2025 | Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.93 | 2019 | |
| Pfizer INC. | $48.50 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.22 | 2019-2020 | |
| Shire North American Group INC | $36.80 | 2019 | |
| Astellas Pharma US INC | $34.62 | 2019 | |
| Mylan Specialty L.P. | $29.00 | 2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $28.62 | 2019 | |
| Aimmune Therapeutics, INC. | $22.73 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $18.27 | 2020 | |
| Genentech USA, INC. | $16.82 | 2019 | |
| Ibsa Pharma INC. | $13.95 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Na Vang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.